Oric Pharmaceuticals/$ORIC
1D1W1MYTD1Y5YMAX
Capital at risk
About Oric Pharmaceuticals
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
- Ticker
- $ORIC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 111
- Headquarters
- South San Francisco, United States
- Website
- www.oricpharma.com
ORIC Metrics
BasicAdvanced
$1.3B
-
-$1.35
0.97
-
Price and volume
Market cap
$1.3B
Beta
0.97
52-week high
$14.93
52-week low
$7.23
Average daily volume
1.3M
Financial strength
Current ratio
13.186
Quick ratio
12.756
Long term debt to equity
0.007
Total debt to equity
0.016
Profitability
EBITDA (TTM)
-154.995
Management effectiveness
Return on assets (TTM)
-25.97%
Return on equity (TTM)
-39.80%
Valuation
Price to book
3.44
Price to tangible book (TTM)
3.44
Price to free cash flow (TTM)
-11.704
Free cash flow yield (TTM)
-8.54%
Free cash flow per share (TTM)
-1.081
Growth
Earnings per share change (TTM)
-28.52%
3-year earnings per share growth (CAGR)
-14.64%
What the Analysts think about ORIC
Analyst ratings (Buy, Hold, Sell) for Oric Pharmaceuticals stock.
Analyst projections of the future price of Oric Pharmaceuticals stock.
Bulls say / Bears say
Initiation of the global Phase 3 Himalayas-1 trial of ORIC-944 (rinzimetostat) in combination with darolutamide in post-abiraterone mCRPC de-risks the lead program and marks a major pipeline milestone (GlobeNewswire)
Strategic collaboration with Bayer under which ORIC retains full global rights to rinzimetostat while receiving darolutamide supply reduces trial costs and validates ORIC’s asset with a top-tier pharma partner (GlobeNewswire)
Robust balance sheet with $387.6 million in cash, cash equivalents and investments as of June 30, 2026 provides funding into 2H 2028, mitigating near-term dilution risks (GlobeNewswire)
R&D expenses rose 19% year-over-year to $36.3 million in Q2 2026, reflecting accelerated cash burn to advance late-stage programs (GlobeNewswire)
Net quarterly loss widened 14% to $41.5 million in Q2 2026, underlining continued high operating losses before any product revenue (GlobeNewswire)
With key clinical updates for enozertinib (ORIC-114) not expected until 2H 2026, the company faces binary event risk that could trigger significant stock volatility (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
ORIC Financial Performance
Revenues and expenses
ORIC Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ORIC
AllUSDGBPEUR
Fund name | Fund size | $ORIC weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.09% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.